Strategies for maximizing photothermal conversion efficiency based on organic dyes

Weng, Xiao-Lu; Liu, Jian-Yong

doi:10.1016/j.drudis.2021.03.009

Cited by 55 publications

(29 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, many efforts have been made to improve PCE (168). Reducing the fluorescence emission and inhibiting the singlet to triplet state intersystem crossing (ISC) reaction are valuable strategies for improving heat generation (169). In addition, reducing tumor heat tolerance is another strategy to address this problem.…”

Section: Discussionmentioning

confidence: 99%

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer

Zhao

Liu²,

Liu³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) therapy has evolved as a revolutionized therapeutic modality to eradicate tumor cells by releasing the brake of the antitumor immune response. However, only a subset of patients could benefit from ICB treatment currently. Phototherapy usually includes photothermal therapy (PTT) and photodynamic therapy (PDT). PTT exerts a local therapeutic effect by using photothermal agents to generate heat upon laser irradiation. PDT utilizes irradiated photosensitizers with a laser to produce reactive oxygen species to kill the target cells. Both PTT and PDT can induce immunogenic cell death in tumors to activate antigen-presenting cells and promote T cell infiltration. Therefore, combining ICB treatment with PTT/PDT can enhance the antitumor immune response and prevent tumor metastases and recurrence. In this review, we summarized the mechanism of phototherapy in cancer immunotherapy and discussed the recent advances in the development of phototherapy combined with ICB therapy to treat malignant tumors. Moreover, we also outlined the significant progress of phototherapy combined with targeted therapy or chemotherapy to improve ICB in preclinical and clinical studies. Finally, we analyzed the current challenges of this novel combination treatment regimen. We believe that the next-generation technology breakthrough in cancer treatment may come from this combinational win-win strategy of photoimmunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer

Zhao

Liu²,

Liu³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…157,158 PDT uses a nontoxic drug that is activated by irradiation, which causes the generation of cytotoxic reactive oxygen species, particularly singlet oxygen ( 1 O 2 ) that kills the cancer cells. 159 For high therapeutic benefits and minimal toxic effects, a high accumulation of PDT drug in the cancer cell is required. PDT agents were successfully delivered using the ND platform.…”

Section: Delivery Of Photodynamic Therapeuticsmentioning

confidence: 99%

Nanodiscs: a versatile nanocarrier platform for cancer diagnosis and treatment

Bariwal

Altenberg

et al. 2022

Chem. Soc. Rev.

View full text Add to dashboard Cite

show abstract

“…Researchers are still taking great efforts to optimize the PTT performance of different types of PTAs. Recently, boron dipyrromethene (BODIPY)-based derivatives have been extensively applied in fluorescence imaging and PTT via specific molecular modifications. , Peng’s team reported a novel BODIPY-based PTA that exhibited ultrahigh photothermal conversion efficiency by introducing a trifluoromethyl (−CF 3 ) barrier-free rotor into the meso -position of the BODPIY scaffold . This new “barrier-free rotation” concept could be a valid strategy to enhance nonradiative decay pathways and intensify the conversion efficiency of absorbed light into thermal energy.…”

Section: Introductionmentioning

confidence: 99%

A Hypoxia-Activated Prodrug Conjugated with a BODIPY-Based Photothermal Agent for Imaging-Guided Chemo-Photothermal Combination Therapy

Yang

Wen

et al. 2022

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

Hypoxia-activated prodrugs (HAPs) have drawn increasing attention for improving the antitumor effects while minimizing side effects. However, the heterogeneous distribution of the hypoxic region in tumors severely impedes the curative effect of HAPs. Additionally, most HAPs are not amenable to optical imaging, and it is difficult to precisely trace them in tissues. Herein, we carefully designed and synthesized a multifunctional therapeutic BAC prodrug by connecting the chemotherapeutic drug camptothecin (CPT) and the fluorescent photothermal agent boron dipyrromethene (BODIPY) via hypoxia-responsive azobenzene linkers. To enhance the solubility and tumor accumulation, the prepared BAC was further encapsulated into a human serum albumin (HSA)-based drug delivery system to form HSA@BAC nanoparticles. Since the CPT was caged by a BODIPY-based molecule at the active site, the BAC exhibited excellent biosafety. Importantly, the activated CPT could be quickly released from BAC and could perform chemotherapy in hypoxic cancer cells, which was ascribed to the cleavage of the azobenzene linker by overexpressed azoreductase. After irradiation with a 730 nm laser, HSA@BAC can efficiently generate hyperthermia to achieve irreversible cancer cell death by oxygen-independent photothermal therapy. Under fluorescence imaging-guided local irradiation, both in vitro and in vivo studies demonstrated that HSA@BAC exhibited superior antitumor effects with minimal side effects.

show abstract

Strategies for maximizing photothermal conversion efficiency based on organic dyes

Cited by 55 publications

References 63 publications

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer

Nanodiscs: a versatile nanocarrier platform for cancer diagnosis and treatment

A Hypoxia-Activated Prodrug Conjugated with a BODIPY-Based Photothermal Agent for Imaging-Guided Chemo-Photothermal Combination Therapy

Contact Info

Product

Resources

About